Cargando…
Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort
Introduction: In relapsing Multiple Sclerosis (RMS) patients treated with disease modifying drugs (DMDs), few data are available regarding the biomarkers of treatment response. We aimed to assess the predictive value of lymphocyte count (LC) and Body Mass Index (BMI) for treatment response in a real...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587065/ https://www.ncbi.nlm.nih.gov/pubmed/31258529 http://dx.doi.org/10.3389/fimmu.2019.01343 |
_version_ | 1783428998646202368 |
---|---|
author | Manni, Alessia Iaffaldano, Antonio Lucisano, Giuseppe D'Onghia, Mariangela Mezzapesa, Domenico Maria Felica, Vincenzo Iaffaldano, Pietro Trojano, Maria Paolicelli, Damiano |
author_facet | Manni, Alessia Iaffaldano, Antonio Lucisano, Giuseppe D'Onghia, Mariangela Mezzapesa, Domenico Maria Felica, Vincenzo Iaffaldano, Pietro Trojano, Maria Paolicelli, Damiano |
author_sort | Manni, Alessia |
collection | PubMed |
description | Introduction: In relapsing Multiple Sclerosis (RMS) patients treated with disease modifying drugs (DMDs), few data are available regarding the biomarkers of treatment response. We aimed to assess the predictive value of lymphocyte count (LC) and Body Mass Index (BMI) for treatment response in a real life setting of dimethyl fumarate (DMF) treated patients. Materials and Methods: We included in our observational analysis 338 patients who were prescribed DMF in an Italian MS Center. We collected clinical and demographic data at the beginning of DMF (T0), and assessed White Blood Cells (WBC) and LC at T0 and at 3 (T3), 6 (T6), 9 (T9), and 12 (T12) months. Gadolinium enhancing (Gd+), new T2 lesions and relapses within the first year of treatment (T12) were recorded in order to evaluate clinical activity at 12 months. Analysis of correlation was performed to correlate WBC, LC and BMI with clinical and radiological responses. We evaluated whether BMI or LC can predict treatment response by using multivariate logistic regression models at each follow-up. Results: Our cohort was followed up for a mean period of 19.8 ± 6.8 months. The mean BMI at baseline was 24.19 ± 4.48. The multivariate models gave as predictive factors for Gd+ lesions at T12, LC at T3 (OR = 1.003, 95% CI = 1.00-1.07; p = 0.046) and baseline BMI (OR = 0.71, 95% CI = 0.52–0.98; p = 0.037). Predictive factors for new T2 lesions at T12 were LC at T3 (OR = 1.01 95%CI = 1.00–1.95; p = 0.005) and baseline BMI (OR = 0.99, 95% CI = 0.98–1.00; p = 0.026). Conclusions: In our real life-experience, BMI and LC may be early biomarkers to predict treatment response during DMF. |
format | Online Article Text |
id | pubmed-6587065 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65870652019-06-28 Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort Manni, Alessia Iaffaldano, Antonio Lucisano, Giuseppe D'Onghia, Mariangela Mezzapesa, Domenico Maria Felica, Vincenzo Iaffaldano, Pietro Trojano, Maria Paolicelli, Damiano Front Immunol Immunology Introduction: In relapsing Multiple Sclerosis (RMS) patients treated with disease modifying drugs (DMDs), few data are available regarding the biomarkers of treatment response. We aimed to assess the predictive value of lymphocyte count (LC) and Body Mass Index (BMI) for treatment response in a real life setting of dimethyl fumarate (DMF) treated patients. Materials and Methods: We included in our observational analysis 338 patients who were prescribed DMF in an Italian MS Center. We collected clinical and demographic data at the beginning of DMF (T0), and assessed White Blood Cells (WBC) and LC at T0 and at 3 (T3), 6 (T6), 9 (T9), and 12 (T12) months. Gadolinium enhancing (Gd+), new T2 lesions and relapses within the first year of treatment (T12) were recorded in order to evaluate clinical activity at 12 months. Analysis of correlation was performed to correlate WBC, LC and BMI with clinical and radiological responses. We evaluated whether BMI or LC can predict treatment response by using multivariate logistic regression models at each follow-up. Results: Our cohort was followed up for a mean period of 19.8 ± 6.8 months. The mean BMI at baseline was 24.19 ± 4.48. The multivariate models gave as predictive factors for Gd+ lesions at T12, LC at T3 (OR = 1.003, 95% CI = 1.00-1.07; p = 0.046) and baseline BMI (OR = 0.71, 95% CI = 0.52–0.98; p = 0.037). Predictive factors for new T2 lesions at T12 were LC at T3 (OR = 1.01 95%CI = 1.00–1.95; p = 0.005) and baseline BMI (OR = 0.99, 95% CI = 0.98–1.00; p = 0.026). Conclusions: In our real life-experience, BMI and LC may be early biomarkers to predict treatment response during DMF. Frontiers Media S.A. 2019-06-14 /pmc/articles/PMC6587065/ /pubmed/31258529 http://dx.doi.org/10.3389/fimmu.2019.01343 Text en Copyright © 2019 Manni, Iaffaldano, Lucisano, D'Onghia, Mezzapesa, Felica, Iaffaldano, Trojano and Paolicelli. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Manni, Alessia Iaffaldano, Antonio Lucisano, Giuseppe D'Onghia, Mariangela Mezzapesa, Domenico Maria Felica, Vincenzo Iaffaldano, Pietro Trojano, Maria Paolicelli, Damiano Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort |
title | Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort |
title_full | Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort |
title_fullStr | Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort |
title_full_unstemmed | Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort |
title_short | Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort |
title_sort | lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587065/ https://www.ncbi.nlm.nih.gov/pubmed/31258529 http://dx.doi.org/10.3389/fimmu.2019.01343 |
work_keys_str_mv | AT mannialessia lymphocytecountandbodymassindexasbiomarkersofearlytreatmentresponseinamultiplesclerosisdimethylfumaratetreatedcohort AT iaffaldanoantonio lymphocytecountandbodymassindexasbiomarkersofearlytreatmentresponseinamultiplesclerosisdimethylfumaratetreatedcohort AT lucisanogiuseppe lymphocytecountandbodymassindexasbiomarkersofearlytreatmentresponseinamultiplesclerosisdimethylfumaratetreatedcohort AT donghiamariangela lymphocytecountandbodymassindexasbiomarkersofearlytreatmentresponseinamultiplesclerosisdimethylfumaratetreatedcohort AT mezzapesadomenicomaria lymphocytecountandbodymassindexasbiomarkersofearlytreatmentresponseinamultiplesclerosisdimethylfumaratetreatedcohort AT felicavincenzo lymphocytecountandbodymassindexasbiomarkersofearlytreatmentresponseinamultiplesclerosisdimethylfumaratetreatedcohort AT iaffaldanopietro lymphocytecountandbodymassindexasbiomarkersofearlytreatmentresponseinamultiplesclerosisdimethylfumaratetreatedcohort AT trojanomaria lymphocytecountandbodymassindexasbiomarkersofearlytreatmentresponseinamultiplesclerosisdimethylfumaratetreatedcohort AT paolicellidamiano lymphocytecountandbodymassindexasbiomarkersofearlytreatmentresponseinamultiplesclerosisdimethylfumaratetreatedcohort |